The Company has received $150,000 in funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to develop a proof of concept for Canurta’s respiratory disease therapeutics.
Canurta is positioned to address respiratory disease by preventing viral infection/replication and treating associated implications, including inflammation.
March 13, 2023
Mississauga, Ontario
Canurta, a preclinical biotechnology company pioneering the discovery and production of novel, polyphenol ingredients, is pleased to announce that the company has received funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to develop a proof of concept for a respiratory disease therapeutic positioned to address respiratory disease by preventing viral infection/replication and treating associated implications, including inflammation.
The funding stems from a challenge issued by the National Research Council of Canada (NRC) through the Federal Government’s Innovative Solutions Canada (ISC) program. The funding will allow Canurta to demonstrate the scientific, technical and commercial merit of our respiratory therapeutic asset, which includes designing various assays to test and evaluate several key activities to achieve essential outcomes, including evaluation of future human clinical assessment.
“We are thrilled to achieve this support from NRC IRAP as it is initial validation of the ability of botanical ingredients to treat complex diseases such as respiratory disease. Canurta will use this funding to continue pushing the boundaries of innovation and create solutions that positively impact the world,” said Akeem Gardner, CEO of Canurta.
Stay tuned for updates on Canurta’s progress and the exciting developments to come.
About Canurta
Canurta is a preclinical biotechnology company pioneering the discovery and production of novel, polyphenol ingredients to improve chronic disease prevention and recovery for humans and animals. Canurta’s vision is to reverse the global rise in chronic disease with transformative natural solutions. With AI-driven research and technology, Canurta unlocks the significant anti-inflammatory, anti-viral, anti-cancer and neuroprotective potential of plant polyphenols.
For further information: hello@canurta.com